Latest news

Clinical

Zealand’s obesity medication fails once more in phase 3

Boehringer Ingelheim's survodutide drug has achieved the co-primary endpoints in a phase 3 trial in adults with obesity and...
Manufacturing

BD Plans Huge U.S. Investment to Expand Medical Manufacturing

BD is preparing a major expansion of its U.S. operations, adding to a growing list of healthcare companies increasing...
Clinical

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

ArriVent BioPharma reported that its phase 3 Furvent trial of firmonertinib in previously untreated patients with non-squamous locally advanced...
Insights

How Healthcare Organizations Are Building AI Centers of Excellence

   Executive Summary Artificial intelligence is moving from isolated healthcare experiments toward broader organizational adoption. Hospitals, health systems, pharmaceutical companies, insurers, and...
Insights

Top 10 Emerging Modalities Beyond RNA Therapeutics

Executive Summary Pharmaceutical innovation is expanding beyond conventional small molecules...
Manufacturing

FDA Warns Fresenius Kabi Over Manufacturing Deviations Linked to Famotidine Adverse Event Reports

The U.S. Food and Drug Administration (FDA) has issued...
Commercial

Novartis agrees to pay Abogen $7.8 billion for its in vivo autoimmune T-cell engager

Novartis-Abogen Deal & Background Novartis has agreed to pay Abogen Biosciences $575 million up front for an mRNA-encoded T-cell engager...
Regulatory

Grail’s cancer blood test on the brink of receiving groundbreaking FDA approval

An advisory panel to the US Food and Drug Administration handed Grail's Galleri blood test a milestone win, saying...
Clinical

Pfizer Reports Phase 3 Results for Litfulo and Phase 2 Atopic Dermatitis Data for Tilrekimig

Pfizer has presented detailed results from two phase 3 clinical trials evaluating its oral Janus kinase (JAK) inhibitor Litfulo...
Insights

Top 10 ESG Priorities for Life Sciences Companies

Executive Summary Environmental, social, and governance (ESG) priorities are becoming...
Insights

Continuous Manufacturing in Pharma Explained

Executive Summary Pharmaceutical manufacturing has traditionally relied on batch production,...
Insights

Why Digital Manufacturing Is Becoming Essential

Executive Summary Pharmaceutical manufacturing is entering a period of significant technological change. Manufacturing facilities are generating more data from equipment, sensors,...
Insights

Top 10 Technologies Modernizing Trial Monitoring

Executive Summary Clinical trial monitoring is undergoing a significant shift as sponsors move beyond traditional site visits and manual data...
Commercial

Merck anticipates a significant win for the $3 billion eye disease opportunity

Trial Success & Key Visual Acuity Results Merck & Co.'s Brunello trial has achieved its primary endpoint, offering more clues...
Commercial

Life Sciences Voice In Collaboration With Future Pharma EU 2026

Future Pharma Europe returns on 20–21 October 2026 in...
Editorial Team -
Commercial

Novartis agrees to pay Abogen $7.8 billion for its in vivo autoimmune T-cell engager

Novartis-Abogen Deal & Background Novartis has agreed to pay Abogen...
Editorial Team -
Commercial

Ipsen to Acquire Memo and Phase 2 BKPyV Antibody Potravitug in Deal Worth Up to €700 Million

French pharmaceutical company Ipsen has agreed to acquire Switzerland-based...
Commercial

Novartis and Alteogen sign a $3.2 billion subcutaneous medication delivery agreement

With South Korea's Alteogen, Novartis has secured access to...

Popular

Most popular life news you must read today

View all articles

Commercial

Information Technology

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Suki announced Tuesday the release of Suki Dictation, an artificial intelligence-powered dictation solution designed...
Editorial Team -

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

Healthcare-related infections remain a persistent challenge for hospitals, affecting roughly one in every 40...
Editorial Team -

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

The U.S. Food and Drug Administration (FDA) granted Johnson & Johnson De Novo clearance...
Editorial Team -

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Alnylam has entered into a partnership with the scientist instrumental in developing the technology...
Editorial Team -

Regulatory

Manufacturing

BD Plans Huge U.S. Investment to Expand Medical Manufacturing

BD is preparing a major expansion of its U.S....
Clinical

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

ArriVent BioPharma reported that its phase 3 Furvent trial...
Insights

How Healthcare Organizations Are Building AI Centers of Excellence

   Executive Summary Artificial intelligence is moving from isolated healthcare experiments...
Insights

The Rise of Platform Biotech Companies

Executive Summary Biotechnology companies have traditionally been built around individual...

Research & Development

Market Access

Manufacturing

Genentech signs a $490 million breast cancer partnership and lays off 103 employees with gRED Rethink

The Roche subsidiary has just announced that the restructuring...
Manufacturing

fda selects seven drugmakers for precheck pilot to accelerate u.s. manufacturing reviews

The U.S. Food and Drug Administration (FDA) has selected...

Manufacturing & RegulatoryPOPULAR
Find Your Perfect Music Festival

Clinical

Zealand’s obesity medication fails once more in phase 3

Boehringer Ingelheim's survodutide drug has achieved the co-primary endpoints...
Editorial Team -
Clinical

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

ArriVent BioPharma reported that its phase 3 Furvent trial...
Editorial Team -